← Compound index
COMPOUND RECORD / CERLUTEN

CerlutenЦерлутен

An animal brain-derived peptide mixture investigated in institute reports and used in the Gazprom occupational research program.

Source linked

What the studies found

Comparison in people · 2007

Oral Cerluten with injected Cortexin in older women with vascular encephalopathy

Study of multiple preparations

Psychosomatic severity · days 30–31
18.04 combined, 24.13 Cortexin, 30.49 usual careLower values indicate lower severity. Baseline means 82.52, 80.12 and 81.52.
Recovery index · days 30–31
85.4 combined, 78.6 Cortexin, 68.7 usual careTable 2. A separate prose value for the combined group is 88.32.
Repeat medical visits · six months
23/54, 31/45 and 57/68By original group order: combination, Cortexin, usual care. Both original peptide arms received Cerluten during follow-up. Table 5 lists repeat medical visits as a proportion of each group.

At days 30–31, psychosomatic severity scores were 18.04 with Cerluten plus Cortexin, 24.13 with Cortexin alone as an adjunct, and 30.49 with usual care. All three groups improved.

Study notes · methods, sources and limitations

Participants or model 167 women aged 65–74 with stage II dyscirculatory encephalopathy. Usual care 68, usual care plus Cortexin 45, usual care plus Cortexin and Cerluten 54.

Design Three usual-care groups: care alone (68), plus injected Cortexin (45), or plus injected Cortexin and oral Cerluten (54). Both peptide arms later took a 60-day Cerluten course.

Important limitations

  • The accessible author abstract does not describe random allocation or masking. The severity scale was developed within the study. The initial comparison had no oral Cerluten-only arm. At follow-up both prior peptide arms received Cerluten, so earlier treatment and group differences may account for some of the difference in repeat visits. The accessible transcription omits a clear harms inventory. Follow-up figures do not establish prevention of stroke or dementia.
  • All groups improved. The comparison cannot establish how oral Cerluten would perform by itself or explain the later differences in medical visits.

St Petersburg, 2007 dissertation author abstract, Russian transcription · Dissertation author abstract

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2006

Cerluten: clinical report on a tissue-derived preparation

The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 85 patients: 48 adjunctive Cerluten; 37 conventional-care controls. Mixed neurological diagnoses.

Important limitations

  • Random allocation and blinding are not documented. EEG assessment selected more severely affected patients; the findings cannot establish stroke recovery or benefit in healthy people. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗

Observational study · 2016

Personified prevention of diseases under the conditions of the Far North

Study of multiple preparations

Sick-leave certificates
18 → 102014 → 2015; whole program
Days unfit for work
119 → 602014 → 2015; whole program
Seasonal morbidity
No statistically reliable improvement reported

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

More reported outcomes
Narrative/table discrepancy
Narrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Study notes · methods, sources and limitations

Participants or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Design 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Important limitations

  • One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Vrach. 2016;(6):64–66 · Journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Cerluten

Identity / background source ↗

Research background

Brain-associated tissue-peptide preparation named in risk-based assignments in the 113-worker Gazprom program and in institute reports. Shared program findings do not isolate Cerluten.

Russian conference citations ↗

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Historical program and institute-report evidence; product-specific outcomes unresolved

Study methods

Original Gazprom PDF plus separately attributed product reports

Independent replication

Independent replication not established in this collection

Source access

Primary-publication records linked; full-text versus abstract review shown per source

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

The 2016 Gazprom report lists Cerluten in its treatment assignments. The size and outcomes of the Cerluten group remain unclear.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2013

Suprefort with and without Cerluten and Endoluten in type 2 diabetes

The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.

Study notes and original source
2013Human comparative studyRussian-language source

Suprefort with and without Cerluten and Endoluten in type 2 diabetes

Oral pancreas, brain and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.

Results and tables

Reported findings and study design

Moscow, February 2011 to April 2012. Standard treatment alone (329), plus Suprefort (214), or plus Suprefort, Cerluten and Endoluten (375). Suprefort and Cerluten were given orally as two capsules each per day for three months. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified in this source.

Population or model 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.

Results · Russian conference reproduction, pp. 11–13, and matching English edition
MeasureResultComparison, timing and statistics
Glucose two hours after challenge9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination.Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable.
Fasting glucose6.8 ± 0.6, 6.1 ± 0.5 and 5.6 ± 0.4 mmol/L, respectively.Both adjunctive arms are marked significant versus standard care.
Standard medication dose reportedly reduced0/329 standard care, 114/214 (53.3%) added Suprefort, 279/375 (74.4%) three-product combination.Medication-adjustment criteria and timing are unspecified.
Glucose response countsSuprefort arm: 195/214 (91.1%) reached the reported upper normal limit by day 18. Three-product arm: 348/375 (92.8%) reportedly normalized by day 12.These outcomes use different assessment days and wording.
Blood glucose in the three reported groups
Blood glucose in the three reported groups
Treatment groupParticipantsFasting beforeFasting afterTwo-hour beforeTwo-hour after
Standard care3298.4 ± 0.66.8 ± 0.613.8 ± 0.49.7 ± 0.5
Standard care + Suprefort2148.2 ± 0.76.1 ± 0.513.4 ± 0.67.3 ± 0.6
Standard care + Suprefort, Cerluten and Endoluten3758.3 ± 0.75.6 ± 0.413.6 ± 0.66.5 ± 0.4

Glucose in mmol/L. Table 3 leaves the timing and the meaning of the ± term unspecified.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. The reports do not give a systematic harms assessment. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
Source reviewed
Authors’ conference material, Russian reproduction, PDF pages 11–13, methods and Table 3. English and Russian editions describe the same cohort.
Study limitations
  • Allocation, masking, treatment adjustments, exact timing of Table 3 and analysis denominators are unspecified. The response counts use different assessment days.
  • The 918-person Moscow comparison has a different site and design from the 59-person St. Petersburg Medical Center report. Participant-level linkage is unavailable.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2013

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Study notes and original source
2013Human comparative studyRussian-language source

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Results and tables

Reported findings and study design

Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.

Population or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Results · Russian conference reproduction, pp. 8–10, and matching English edition
MeasureResultComparison, timing and statistics
Total cholesterol7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
VLDL cholesterol1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
Reported fatigue64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Source reviewed
Authors’ conference material, Russian reproduction, PDF pages 8–10, methods and Tables 1–2. English and Russian editions describe the same comparison.
Study limitations
  • The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten.
  • Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods.
  • The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified.
  • Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2007

Oral Cerluten with injected Cortexin in older women with vascular encephalopathy

At days 30–31, psychosomatic severity scores were 18.04 with Cerluten plus Cortexin, 24.13 with Cortexin alone as an adjunct, and 30.49 with usual care. All three groups improved.

Study notes and original source
2007Human comparative studyRussian-language source

Oral Cerluten with injected Cortexin in older women with vascular encephalopathy

Oral Cerluten tablets (also named Ceremax in the author abstract) and intramuscular Cortexin. · Dissertation author abstract

G. L. Zhernakov · St Petersburg, 2007 dissertation author abstract, Russian transcription

At days 30–31, psychosomatic severity scores were 18.04 with Cerluten plus Cortexin, 24.13 with Cortexin alone as an adjunct, and 30.49 with usual care. All three groups improved.

Results and tables

Reported findings and study design

Three usual-care groups: care alone (68), plus injected Cortexin (45), or plus injected Cortexin and oral Cerluten (54). Both peptide arms later took a 60-day Cerluten course.

Population or model 167 women aged 65–74 with stage II dyscirculatory encephalopathy. Usual care 68, usual care plus Cortexin 45, usual care plus Cortexin and Cerluten 54.

Dose, route and schedule

Both peptide arms received Cortexin 10 mg intramuscularly once daily for 10 days. The combined arm added Cerluten two tablets twice daily for 30 days. One month later, both peptide arms received Cerluten two tablets twice daily for 60 days. The Cerluten mass per tablet is unspecified.

Protocol source ↗ · Russian author-abstract transcription, methods and Tables 2 and 5

Results · Russian author-abstract transcription, methods and Tables 2 and 5
MeasureResultComparison, timing and statistics
Psychosomatic severity · days 30–3118.04 combined, 24.13 Cortexin, 30.49 usual careLower values indicate lower severity. Baseline means 82.52, 80.12 and 81.52.
Recovery index · days 30–3185.4 combined, 78.6 Cortexin, 68.7 usual careTable 2. A separate prose value for the combined group is 88.32.
Repeat medical visits · six months23/54, 31/45 and 57/68By original group order: combination, Cortexin, usual care. Both original peptide arms received Cerluten during follow-up. Table 5 lists repeat medical visits as a proportion of each group.
Table 2 · psychosomatic severity scores
Table 2 · psychosomatic severity scores
Initial treatmentBaselineDays 10–11Days 20–21Days 30–31
Usual care81.52 ± 2.7563.34 ± 1.7540.43 ± 1.2430.49 ± 3.40
Usual care + Cortexin80.12 ± 5.3260.15 ± 1.5038.09 ± 1.3324.13 ± 3.16
Usual care + Cortexin + Cerluten82.52 ± 3.4758.30 ± 1.9035.24 ± 2.3218.04 ± 4.23

Means and ± values as reproduced. The available transcription flattens the p-value columns, so pairwise p-values are omitted.

All groups improved. The comparison cannot establish how oral Cerluten would perform by itself or explain the later differences in medical visits.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
167 women aged 65–74 with stage II dyscirculatory encephalopathy. Usual care 68, usual care plus Cortexin 45, usual care plus Cortexin and Cerluten 54.
Source reviewed
Russian author-abstract transcription, methods and Tables 2 and 5
Study limitations
  • The accessible author abstract does not describe random allocation or masking. The severity scale was developed within the study. The initial comparison had no oral Cerluten-only arm.
  • At follow-up both prior peptide arms received Cerluten, so earlier treatment and group differences may account for some of the difference in repeat visits.
  • The accessible transcription omits a clear harms inventory. Follow-up figures do not establish prevention of stroke or dementia.

Reviewed 2026-11-14.

Read the source ↗

Observational study · 2016

Personified prevention of diseases under the conditions of the Far North

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

Study notes and original source
2016Uncontrolled human reportFull text available

Personified prevention of diseases under the conditions of the Far North

Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments · Journal publication

S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy · Vrach. 2016;(6):64–66

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

Results and tables

Reported findings and study design

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Population or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Dose, route and schedule

One capsule of the assigned preparation daily for 20 days. Products were selected by risk assessment; all six products were not given to every participant.

Protocol source ↗ · Original PDF p.65

Results · Original publisher PDF pp.64–66; Table 2 visually checked
MeasureResultComparison, timing and statistics
Sick-leave certificates18 → 102014 → 2015; whole program
Days unfit for work119 → 602014 → 2015; whole program
Seasonal morbidityNo statistically reliable improvement reported
Narrative/table discrepancyNarrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Table 2 · Chronic-disease recurrence-related sick leave
Table 2 · Chronic-disease recurrence-related sick leave
Measure20142015
Sick-leave certificates1810
Days unfit for work11960

Historical comparison for the shared 113-worker program. Not preparation-specific results.

One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Source reviewed
Original publisher PDF methods and clinical table checked; table visually verified.
Study limitations
  • One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 2006

Cerluten: clinical report on a tissue-derived preparation

The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.

Study notes and original source
2006Human comparative studyRussian-language source

Cerluten: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date

The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.

Population / setting
85 patients: 48 adjunctive Cerluten; 37 conventional-care controls. Mixed neurological diagnoses.
Source reviewed
Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
  • Random allocation and blinding are not documented. EEG assessment selected more severely affected patients; the findings cannot establish stroke recovery or benefit in healthy people.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-10-02.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗